Troisi Marco, Marini Eleonora, Abbiento Valentina, Stazzoni Samuele, Andreano Emanuele, Rappuoli Rino
Monoclonal Antibody Discovery (MAD) Laboratory, Fondazione Toscana Life Sciences, Siena, Italy.
Department of Biotechnology, Chemistry and Pharmacy, University of Siena, Siena, Italy.
Front Microbiol. 2022 Dec 14;13:1080059. doi: 10.3389/fmicb.2022.1080059. eCollection 2022.
Antimicrobial resistance (AMR) is a quickly advancing threat for human health worldwide and almost 5 million deaths are already attributable to this phenomenon every year. Since antibiotics are failing to treat AMR-bacteria, new tools are needed, and human monoclonal antibodies (mAbs) can fill this role. In almost 50 years since the introduction of the first technology that led to mAb discovery, enormous leaps forward have been made to identify and develop extremely potent human mAbs. While their usefulness has been extensively proved against viral pathogens, human mAbs have yet to find their space in treating and preventing infections from AMR-bacteria and fully conquer the field of infectious diseases. The novel and most innovative technologies herein reviewed can support this goal and add powerful tools in the arsenal of weapons against AMR.
抗菌药物耐药性（AMR）是全球人类健康面临的一个迅速发展的威胁，每年已有近500万人死亡可归因于这一现象。由于抗生素无法治疗AMR细菌，因此需要新的工具，而人源单克隆抗体（mAb）可以发挥这一作用。自导致mAb发现的第一项技术问世近50年来，在识别和开发极其有效的人源mAb方面已经取得了巨大飞跃。虽然它们对病毒病原体的有效性已得到广泛证明，但人源mAb在治疗和预防AMR细菌感染方面尚未找到用武之地，也尚未完全征服传染病领域。本文综述的新颖且最具创新性的技术可以支持这一目标，并为对抗AMR的武器库增添强大工具。
